Through genomic research, we continue to learn more about the complexity of cancer. While cancer continues to be identified by its location in the body (lung, breast, blood, etc.), we have learned that a more accurate way to evaluate cancer treatment is through examination of the underlying changes or mutations which drive cancer development and progression. Those mutations are not limited to location and, in many instances, have very little correlation with the location. Understanding the core genetic mutations which drive cancer progression allows clinicians to replace more traditional treatments with newer, less toxic, therapies that target those specific mutations.
Targets key regions of 23 genes identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO) to be clinically actionable somatic mutations in solid tumors
GenOnc Cancer Panel 2 – Clinically Relevant Tumor Targeted Panel is a collection of multiplexed PCR primer assays for targeted enrichment of the key regions of 24 genes identified by medical groups and peer-reviewed research to be functionally relevant in the treatment of solid tumors. Clinically relevant mutations in these genes have been identified by guidelines and published opinions from groups such as the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO).
GenOnc Cancer Panel 3 expands the cancer gene repertoire covered in GenOnc Cancer Panels 1 and 2 by targeting genomic “hot spot” regions in 50 human oncogenes and tumor suppressor genes, detecting 2,800 COSMIC mutations frequently found in a variety of human cancers.
The GenOnc Comprehensive Cancer Panel is one of the most comprehensive cancer gene panels available. Encompassing over 50% of the Welcome Trust Sanger Institute Cancer Gene Census, this 409 gene panel targets key tumor suppressor genes and oncogenes that are the most frequently cited and most frequently mutated in cancer. The panel includes genes that function in growth factor and cytokine responses, signaling cascades, apoptosis, DNA repair, cell cycle regulation, transcription regulation, and inflammatory response pathways
Predisposition Targeted Panel is a multiplexed PCR-based assay for targeted enrichment of the coding (exonic) regions of the 145 genes commonly mutated in 88 inherited oncogenic diseases
FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, HRAS, LIG4, MLH1, MSH2, MSH6, PALB2, PIK3CA (p110-alpha), PMS2, PRKAR1A, PTEN, SLX4 (BTBD12), TP53 (p53), VHL.
Bone: EXT1, EXT2, MTAP, RECQL4, TP53 (p53).
Hereditary Breast-Ovarian: BARD1, BRCA1, BRCA2, CHEK2 (RAD53), RAD51B (RAD51L1), RAD51C, RAD51D (RAD51L3).
Colorectal: APC, AXIN2, GALNT12, MLH3, MUTYH, POLD1, POLE.
Endocrine: AIP, CDC73, CDKN1B (P27KIP1), CYP21A2, GLI3, MAX, MEN1, NDUFA13, NTRK1, PDE11A, PRKAR1A, RET, TMEM127, TP53 (p53), VHL.
Gastrointestinal Tract: ASCC1, BMPR1A (ALK3), CDH1 (E-Cadherin), KIT (CD117), MSR1, PDGFRA, PTEN, RHBDF2, SDHC, SMAD4 (MADH4), STK11 (LKB1).
Head & Neck: CYLD, DKC1, RTEL1, TERC, TERT, TINF2, TSC1, TSC2.
Hematopoietic: ATM, CEBPA, GATA2, KLHDC8B, LYST, MRE11A, NBN (NBS1), RAD50, RUNX1(AML1), SBDS, TERT, WAS.
Kidney: DIS3L2, FH, FLCN, MET, MITF, POU6F2, WT1.
Liver: FAH, HFE, UROD.
Nervous System: ALK, GPC3, KIF1B, NF1, NF2, PRKAR1A, RB1, PHOX2B, SDHA, SDHAF2, SDHB, SDHD, SMARCA4, SMARCB1, SUFU.
Skin: BAP1, CDK4, CDKN2A (p16INK4a), CYLD, DDB2, ERCC2 (XPD), ERCC3 (XPB), ERCC4, ERCC5, ERCC6, FH, FLCN, GLMN, MC1R, MITF, MSH2, POLH, PTCH1, PTCH2, RSPO1, TGFBR1(ALK5), TMC6, TMC8, XPA, XPC,
[GenOnc Panel 4 – ]